Non-alcoholic fatty liver disease (NAFLD)—the buildup of fat in the liver not related to alcohol use—ranks as one of the most common causes of chronic liver disease in the United States. Because several promising agents are on the near horizon, specialty pharmacists should prepare to play a key role in the management of this challenging condition.
NAFLD, with a prevalence of up to 25% in the U.S. population, according to the Liver Foundation, often can progress to